What Эрготамина тартрат Treats: Main Uses and Benefits

This medication is used as therapy to address or prevent vascular headache. This means the drug is commonly applied in clinical settings for symptomatic relief of moderate-to-severe vascular headaches, including migraine attacks and cluster headaches. It is considered relevant in clinical settings where supportive management for symptoms is challenging. It is applied in addressing symptom clusters characterized by intense, throbbing head pain, often along with associated debilitating discomfort. The therapeutic benefit supports the patient during episodes of heightened discomfort, which helps patients cope more steadily with difficult episodes and may assist with maintaining functional stability.

---

Key Applications and Benefits

Ergotamine Tartrate is also applied in obstetrical settings for conditions marked by a lack of proper uterine muscle tone (atony or hypotonia) following childbirth or a miscarriage. This therapeutic application is relevant in clinical situations where there may be a risk of excessive or persistent bleeding. The key benefit supports the management of this symptomatic discomfort, which provides supportive assistance that helps ease the overall symptom load and supports general well-being during symptomatic phases, relevant in contexts involving heightened systemic burden during the immediate postpartum phase.

Quick Fact: Symptom Domain
Relief for Severe Throbbing Pain and Postpartum Uterine Weakness

Regulatory References

1. NIH DailyMed overview

The eligibility for using Ergotamine Tartrate is strictly defined by government regulatory documents, primarily due to the drug's potent vasoconstrictive and uterine stimulating properties.

Contraindicated Populations and Conditions

Absolute regulatory contraindications prohibit the use of this medicine in several patient groups, including:

• Vascular Disease: Patients with Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), uncontrolled hypertension, or a history of stroke.
• Organ Function: Individuals with severe impaired hepatic function (liver disease) or impaired renal function (kidney disease).
• Infections: Patients with sepsis (severe blood infection).
• Hypersensitivity: Those with a known allergy to ergotamine or any component of the formulation.

Age and Physiological Status

Status	Official Eligibility Classification
Pregnancy	Contraindicated (FDA Category X) due to the risk of fetal harm and oxytocic effect.
Lactation/Nursing	Contraindicated; a decision must be made to discontinue nursing or discontinue the drug.
Pediatric Use	Safety and efficacy are not established in children and adolescents.
Geriatric Use	Insufficient data is available to establish specific guidelines.

Eligibility Restrictions

Use is officially restricted to the acute management of conditions and is not recommended for chronic, daily administration to mitigate the risk of complications such as fibrotic changes and medication overuse headache. The medicine is also strictly contraindicated if co-administered with other vasoconstrictors or certain potent CYP3A4 inhibitors (e.g., macrolide antibiotics, protease inhibitors).

Interactions with other medicines and products

The interaction profile of Ergotamine Tartrate is officially defined by its core metabolic pathway and potent vasoconstrictive effects, resulting in several formal regulatory restrictions.

Interaction Type	Examples of Interacting Substances/Conditions
Pharmacokinetic: Contraindicated	Potent CYP3A4 Inhibitors, including Macrolide Antibiotics (e.g., erythromycin), Azole Antifungals (e.g., ketoconazole), and HIV Protease Inhibitors (e.g., ritonavir). Co-use is prohibited due to significantly increased plasma concentration and high risk of acute ergot toxicity (ergotism).
Pharmacodynamic: Contraindicated	Triptans (5 HT1 agonists) and Other Vasoconstrictors/Sympathomimetics. Prohibited due to the risk of additive vasospasm, extreme blood pressure elevation, and ischemia.
Clearance-Dependent Restriction	Impaired Hepatic Function and Impaired Renal Function. Contraindicated due to the risk of systemic accumulation and ergot toxicity stemming from impaired drug metabolism and elimination.

Co-administration of ergotamine and Triptans must be separated by a mandatory 24-hour interval. In addition to medicinal products, consumption of Grapefruit juice is officially advised against as it is a known CYP3A4 inhibitor, potentially raising drug exposure. Beta-blockers may officially potentiate the vasoconstrictive action of ergotamine.

Modulating Receptor Activity to Regulate Vascular Dynamics

The core mechanism of Ergotamine Tartrate involves direct agonist action at multiple monoamine receptors, primarily the serotonin receptors (5-HT1B) and alpha-adrenergic receptors (alpha1) on the smooth muscle of extracerebral blood vessels. Activation of these targets initiates a vasoconstrictive cascade, directly narrowing these blood vessels. This process modulates activity within the vascular tone regulatory pathways.

Suppressing Neurogenic Signaling

A complementary action occurs through 5-HT1D receptor agonism on sensory nerve endings, particularly those of the trigeminal system. This mechanism effectively inhibits the release of pro-inflammatory neuropeptides, such as CGRP, thereby resulting in the modulation of processes driven by localized nerve overactivity. This suppression results in an alteration of mediator activity on surrounding tissues.

Sustaining the Physiological Profile

The mechanism is characterized by the drug's non-selective affinity and tight binding to its biological targets, which results in a sustained duration of receptor activation. Additionally, its interactions with alpha1-receptors and the inhibition of the norepinephrine transporter contribute to sustained smooth muscle contraction and the modulation of systemic vascular dynamics.

Ergotamine tartrate is intended exclusively for acute intermittent use and is strictly prohibited for chronic daily administration. The protocol involves rapid, on-demand use, with dosing initiated at the first sign of an episode.

Administration Routes and Dosing

The medicine is available for use via sublingual, oral, and rectal routes, often utilizing fixed combination products. The typical initial dose for an acute episode is 2 mg of ergotamine tartrate. Subsequent doses (usually 1 mg to 2 mg) may be repeated after intervals of 30 minutes for oral/sublingual forms or 1 hour for rectal forms, strictly as necessary.

Rigid constraints apply to the total amount administered. The total dose must not exceed 6 mg in any 24-hour period, nor exceed 10 mg across a seven-day period, regardless of the route used.

Procedural Conditions and Restrictions

Specific methods apply to certain forms. The sublingual tablet must be placed under the tongue and allowed to dissolve completely; it must not be chewed or swallowed. Furthermore, it is advised to avoid the consumption of grapefruit or grapefruit juice while the medication is being used. Standardized dosing regimens are not established for the pediatric or geriatric populations, and use is restricted in the presence of impaired hepatic or renal function.

Research Evidence / Overview of Studies for Ergotamine Tartrate

Evidence for Use in Acute Vascular Headaches

The research exploring the use of Ergotamine Tartrate in conditions associated with acute or disruptive episodes, such as migraine attacks and cluster headaches, includes Randomized Controlled Trials (RCTs) and comparative studies. Studies examined outcomes related to physical discomfort, specifically measuring the change in the intensity of headache pain and associated physical discomfort over short intervals in adult populations. Research so far indicates that some trials, primarily involving short-term evaluations, described patterns observed in the short-term change of physical discomfort. However, certain controlled trials observed that the outcomes related to pain did not show patterns clearly different from placebo. Evidence quality varies across studies. What remains uncertain is the full profile of the research evidence compared with current acute treatments. Evidence is limited because much of the research base originates from studies conducted before current, standardized headache classification criteria were widely used. Furthermore, there is limited information for long-term outcomes.

---

Evidence for Use in Postpartum Uterine Atony

The research base examining the use of Ergotamine Tartrate in conditions marked by insufficient uterine muscle tone (atonicity) following childbirth includes historical clinical data and Controlled Clinical Trials. Research was evaluated in contexts focused on outcomes related to systemic or functional imbalance. Specifically, studies monitored outcomes reflecting physiological strain by measuring the change in uterine tone and the volume of blood loss. Comparative evidence is lacking for Ergotamine Tartrate specifically against contemporary first-line medicines used for this purpose. Many relevant studies observed are associated with its related derivatives, such as ergometrine. The research provides context but not individual predictions, and data for certain groups remain insufficient.

---

The Research Landscape: Consistency and Uncertainty

The overall evidence quality varies across studies, leading to a complex research landscape. Research describes a historical foundation, but findings were mixed in several modern head-to-head comparisons. Many of the clinical trials have modest sample sizes and follow-up durations were limited. Findings were mixed and certainty remains low in the available research base.

Key Studies & References Ergotamine Tartrate Tablet DailyMed Information

Common questions about Эрготамина тартрат (FAQ)

Q: Через какое время после приема начинает действовать Эрготамина тартрат?

A: Official dosing guidelines indicate that subsequent doses, if needed, may be repeated after intervals of 30 minutes (for oral/sublingual forms) or 1 hour (for rectal forms) until the acute episode is relieved. These re-dosing intervals reflect the time window for assessing initial response to the medication, as indicated in official guidelines.

Q: Что делать, если пропустил(а) прием Эрготамина тартрат (например, в случае мигрени)?

A: Regulatory patient information often advises that if a dose is missed, it should generally be taken as soon swelled as it is remembered, unless it is close to the time for the next allowed dose. It is important never to exceed the maximum dose limits set by the label, as the medication is restricted to acute, intermittent use.

Q: Может ли Эрготамина тартрат вызывать онемение конечностей?

A: Official safety information notes that symptoms such as numbness, tingling, coldness, or paleness of the fingers and toes have been reported. These signs are indicators of a serious side effect called peripheral vascular ischemia (ergotism), which involves severe narrowing of blood vessels.

Q: Влияет ли Эрготамина тартрат на способность управлять автомобилем?

A: Official product information cautions that side effects like dizziness, weakness, and severe sleepiness may affect mental alertness. Patients should be aware of these potential effects before driving or operating machinery. Caution is advised during activities requiring full mental focus.

Q: Как хранить Эрготамина тартрат, чтобы он не потерял своих свойств?

A: Regulatory guidelines specify that the medicine should be stored in a tightly closed container at controlled room temperature, typically between 20^circ–25 C. It is important to keep the medicine away from heat, light, and moisture. Improper storage conditions, such as high heat or moisture, can potentially affect the stability of the medicine, according to storage guidelines.

Q: Чем Эрготамина тартрат отличается от обычных обезболивающих при головной боли?

A: This medication is categorized as a specific agent that acts by narrowing blood vessels in the head (vasoconstriction) to treat vascular headaches, such as migraines. Official information states this drug is not indicated for and may not be effective against common headaches caused by muscle-contraction (tension headaches).

Q: В чем разница между Эрготамина тартрат и триптанами?

A: Ergotamine tartrate is classified as a non-selective agent, meaning it activates a broad range of receptors, including serotonin, dopamine, and noradrenaline receptors. Triptans, in comparison, are generally known to have a more selective affinity, primarily targeting only specific serotonin 5 -HT1 receptors. Both classes are restricted from being used together.

Q: Действительно ли Эрготамина тартрат используют в гинекологии/акушерстве, и зачем?

A: The drug is officially classified as a uterine musculature stimulant because it causes the muscles of the uterus to contract (oxytocic action). While historically used to help prevent heavy bleeding after childbirth, it is now strictly contraindicated in pregnancy due to its potent effect on the fetus and uterus.

Q: С какими продуктами питания или напитками несовместим Эрготамина тартрат?

A: Official labeling specifically advises against the consumption of grapefruit and grapefruit juice. This is because they can interfere with the breakdown of the drug in the body, which may increase the risk of toxicity. Nicotine use is also generally advised against while using this medication.

Q: Почему этот препарат иногда используют в составе комплексных лекарств (например, с другими компонентами)?

A: The drug is often found in fixed combination products, most commonly with caffeine. Caffeine is often added because it is believed to help speed up and increase the absorption of ergotamine into the body, which can be beneficial for treating acute migraine episodes.

Q: При каких видах головной боли Эрготамина тартрат неэффективен?

A: The medicine is specifically indicated only for vascular headaches (migraines and cluster headaches). The drug is not labeled for and is considered ineffective against common headaches caused by muscle-contraction (tension headaches).

Q: Может ли Эрготамина тартрат взаимодействовать с травяными добавками?

A: Official regulatory labels advise patients to inform their healthcare provider about all medications, including herbal remedies and supplements. This is necessary because certain herbal products may interact with the drug’s metabolic pathway (CYP3A4), potentially increasing the risk of adverse reactions.

Q: Нужно ли прекращать прием Эрготамина тартрат постепенно?

A: The medication is intended for acute use, so most patients do not require a gradual tapering. However, in cases of prolonged, continuous use (which is not recommended), a gradual reduction of dosage may be discussed with a healthcare provider to manage the potential for rebound headache upon discontinuation.

Q: Какие неочевидные или редкие побочные эффекты могут возникнуть?

A: For patients who use the medicine continuously and long-term, rare reports exist of fibrotic complications. These include thickening of tissues in the body, such as the heart valves (cardiac valvular fibrosis) or tissues surrounding the lungs and abdomen (pleuropulmonary or retroperitoneal fibrosis).

Q: Влияет ли этот препарат на печень или почки?

A: Use of this medication is officially contraindicated (prohibited) in patients with severe liver (hepatic) or kidney (renal) impairment. This restriction is due to the importance of these organs in processing and eliminating the drug, and their impairment could lead to systemic drug accumulation and toxicity.

Q: Есть ли у препарата синдром отмены при прекращении использования?

A: Yes, official information indicates that patients who use the medication in high doses or for extended periods may experience withdrawal symptoms. This is most commonly seen as a rebound headache or medication overuse headache upon discontinuation of the drug.

Q: Правда ли, что Эрготамина тартрат раньше использовали чаще, чем сейчас?

A: Ergotamine tartrate was a foundational drug in treating migraines for many years. Its historical use has been somewhat limited by the emergence of newer classes of specific anti-migraine medications, such as triptans, and the awareness of its potential for serious side effects.

Q: Каков риск развития лекарственной головной боли при приеме Эрготамина тартрат?

A: The risk of developing a medication overuse headache (MOH) is primarily associated with using the drug frequently or in high doses, as it is not intended for chronic daily administration. The official product label imposes strict maximum dose limits, which are intended to mitigate the risk of developing MOH.

Q: Как давно Эрготамина тартрат используется в медицине?

A: The active compound, ergotamine, was first isolated in 1918 from the ergot fungus. It has a long history in medicine, having been introduced specifically for the acute treatment of migraine in the mid-1920s.

Q: Почему у Эрготамина тартрат такие строгие ограничения по дозировке?

A: The drug has very strict limitations on the maximum allowed dose per day and per week. These limits are mandated to minimize the risk of acute toxicity and serious adverse events, primarily intense arterial vasoconstriction, which can lead to peripheral vascular ischemia (ergotism).

Q: Может ли этот препарат влиять на настроение или сон?

A: Yes, official drug information documents list effects on the nervous system, including reports of restlessness and difficulty sleeping (insomnia) as part of the potential side effect profile.

Q: Используется ли Эрготамина тартрат для профилактики мигрени?

A: No. Official labeling indicates the medicine is intended solely for the acute treatment of a migraine attack and is not approved for long-term use as a preventative (prophylactic) medication. Its use is restricted to intermittent, on-demand episodes.

Storage and Disposal Requirements

Official regulatory information specifies strict environmental and handling rules to maintain the quality and safety of Ergotamine Tartrate.

Requirement	Specification
Temperature	Store tablets at Controlled Room Temperature (20^circ– 25 C / 68^circ– 77 F).
Protection	Keep away from heat, light, and moisture. Do not store in the bathroom.
Handling	Keep the container tightly closed and store the medicine in a secured area, inaccessible to children.
Disposal	The preferred method for discard is using drug take-back programs or mail-back envelopes. If these options are unavailable, mix the medicine (not crushed) with an undesirable substance (e.g., dirt) in a sealed bag before disposal in household trash.
Environmental	The substance must not enter drains, and institutional disposal may require classification as hazardous waste, following local and federal regulations.